Amerise Biosciences Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2016 - 2020
Net Income	0.06	-1.46	-1.19	5.49	-3.37	Upgrade
Other Operating Activities	-	-0	-	-	-	Upgrade
Change in Accounts Receivable	-	-	62.17	-62.17	-	Upgrade
Change in Accounts Payable	-	-	-62.66	57.85	-	Upgrade
Change in Other Net Operating Assets	30.65	-0.23	0.36	-0.56	-0.57	Upgrade
Operating Cash Flow	30.71	-1.69	-1.32	0.61	-3.94	Upgrade
Investment in Securities	-1.16	23.01	1.26	-16.51	23.3	Upgrade
Investing Cash Flow	-30.7	2.67	1.26	-1.51	3.89	Upgrade
Short-Term Debt Issued	-	-	0.07	0.83	-	Upgrade
Total Debt Issued	-	-	0.07	0.83	-	Upgrade
Short-Term Debt Repaid	-	-0.9	-	-	-	Upgrade
Total Debt Repaid	-	-0.9	-	-	-	Upgrade
Net Debt Issued (Repaid)	-	-0.9	0.07	0.83	-	Upgrade
Financing Cash Flow	-	-0.9	0.07	0.83	-	Upgrade
Miscellaneous Cash Flow Adjustments	-	-	-0	0	-	Upgrade
Net Cash Flow	0.01	0.08	0.01	-0.06	-0.06	Upgrade
Cash Income Tax Paid	0.02	-	-	-	-	Upgrade
Levered Free Cash Flow	30.7	-1.14	-1.17	-1.44	-2.68	Upgrade
Unlevered Free Cash Flow	30.7	-1.14	-1.17	-1.44	-2.68	Upgrade
Change in Working Capital	30.65	-0.23	-0.13	-4.88	-0.57	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.